Fibroblast growth factor 1 (FGF-1, also known as acidic FGF) is a mitogen for a variety of mesoderm-and neuroectoderm-derived cells, as well as an angiogenic factor in vivo. It has been implicated in angiogenic diseases including atherosclerosis, cancer and inflammatory diseases. In the present study, the entire transcriptional unit of the mouse FGF-1 gene, including four promoters, is characterized. By nucleotide sequence and RNase protection analyses, we have determined that its 3-end resides 3.2 kilobase pairs downstream from the stop codon. We have previously cloned and characterized the mouse homologue of the human 1B promoter, as well as a novel upstream untranslated exon. In order to elucidate the regulatory mechanism of FGF-1 gene expression, the mouse promoter containing TATA and CAAT consensus sequences (FGF-1.A) was isolated from a P1 library and characterized. We further determined that the mouse heart is the most abundant source for the FGF-1.A mRNA. Finally, via both RNase protection analysis and 5-rapid amplification of cDNA ends, we determined the transcription start site of the FGF-1.A mRNA.
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Fibroblast growth factor 1 (FGF-1, also known as acidic FGF)
1 is the prototype, along with FGF-2, of a family of at least 17 related polypeptides that possess broad mitogenic and cell survival abilities (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . These peptides share 30 -60% amino acid sequence identity, a similar exon/intron structure in the protein coding region of the gene, and an affinity for the glycosaminoglycan heparin.
FGF-1 exerts its effect on target cells through high affinity tyrosine kinase cell surface receptors (FGFR1, FGFR2, FGFR3, and FGFR4) (15) and low affinity heparan sulfate proteoglycans (16) . Upon binding to these receptors, FGF-1 elicits a variety of cellular responses, such as differentiation and angiogenesis (17) , as well as tissue repair (18) , wound healing (19) , and cell survival (20) . Although the mechanism of FGF-1 transport and signaling has not been fully unraveled (21) , the current data suggest that this growth factor is exported outside the cell, thereby interacting with cell surface receptors in an autocrine and/or paracrine manner. The lack of a classical signal peptide notwithstanding, endogenous FGF-1 is exported via unconventional secretion pathways, such as in response to oxidative stress (22) , heat shock (23) , and serum starvation (24) .
FGF-1 is expressed in a variety of developing and adult tissues of both mesodermal and neuroectodermal origin, where it promotes their proliferation (25, 26) . More specific to the cardiovascular system, FGF-1 has been shown to have a role in heart development, as it is expressed in heart (27) , cardiac myocytes (28) , smooth muscle cells of the vascular wall (29) , and cultured vascular smooth muscle cells (30) , where it stimulates cell growth by inducing angiotensin converting enzyme (31) .
We have previously cloned and characterized the mouse FGF-1 coding region (32) . It is composed of three protein coding exons of 203 (from the splice acceptor site), 104, and 192 bp (excluding the stop codon and the 3Ј untranslated sequence), similar to its human counterpart (33) . The FGF-1 gene is characterized by both a long 3Ј-untranslated region (UTR) (34) and a complex 5Ј-UTR, which in the human gene is composed of at least four untranslated exons designated Ϫ1A, Ϫ1B, Ϫ1C, and Ϫ1D (35) . The alternative splicing of these untranslated exons to the first protein coding exon generates mRNAs 1.A, 1.B, 1.C, and 1.D, respectively, which are expressed in a tissue-specific manner (35) . The 1.A cDNA, although initially isolated from human brain (36) and kidney (37) , is predominantly expressed in heart and kidney (35, 38) . The 1.B transcript is instead almost exclusively expressed in brain and several glioblastoma cell lines (35, 39) . The remaining two mRNA species are present in various tissue culture cells, with 1.D mRNA being the major transcript (30, 40) . Sufficient evidence now points to FGF-1.A and -1.B transcripts being involved in cell maintenance and survival, particularly in tissues of cardiac and neuronal origin, whereas FGF-1.C and -1.D possibly serve as markers for certain proliferating cells (38) . So far, the most extensively characterized of these upstream exons is the brain-specific 1B promoter (41) (42) (43) .
We have previously cloned the mouse homologue of the Ϫ1B exon (44) . Via in situ hybridization with RNA probes specific for the 1.B transcript, we determined that this message is expressed in the adult mouse sensory and motor nuclei in the midbrain, brain stem, and spinal cord, as well as in the granule cell layer and deep nuclei of the cerebellum (44) . In addition, we have isolated a mouse genomic clone containing a novel 5Ј untranslated exon (45), which we designate Ϫ1G. This exon is * This work was supported by grants R01CA45611 (to I.-M. C.) and K11AI01048 (to K. V. H.) from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The the mouse homologue of the 5Ј-untranslated sequences present in a rat FGF-1 cDNA originally isolated from a rat prostate tumor cDNA library (46) .
To gain a better insight into the expression of FGF-1, we isolated the mouse homologues of the exons Ϫ1A and Ϫ1C. We showed, via RNase protection analysis, that the mouse heart is the most abundant source for the FGF-1.A mRNA. DNA sequence analysis and mapping of the start site of this upstream untranslated exon (located 374 nt 5Ј of the Ϫ1A splice donor site) revealed great similarity with its human homologue (35) . Additionally, we have determined the position of exon Ϫ1A, as well as that of exons Ϫ1B, Ϫ1C, and Ϫ1G, in the mouse FGF-1 locus. Furthermore, via DNA sequencing and RNase protection analysis, we have identified the 3Ј-end of the mouse FGF-1 gene, which resides 3.2 kb downstream of the stop codon. As such, the entire transcriptional unit of the mouse FGF-1 gene spans over 90 kb.
EXPERIMENTAL PROCEDURES
Library Screening-P1 clones 7520, 7521, and 7522 were obtained (Genome Systems, Inc., St. Louis, MO) by polymerase chain reaction (PCR) screening of a P1 library using primers that amplify 109 bp of the mouse FGF-1.B exon. C129SVJ mouse genomic DNA had been partially digested with Sau3AI and cloned into the BamHI site of the P1 cloning vector, pAd10sacBII (47, 48) .
Southern Blotting and Hybridization-P1 DNA and plasmid DNA were prepared via standard methods (49) or using the BIGGERprep® and PERFECTprep TM plasmid isolation kits from 5 Prime 3 3 Prime, Inc. (Boulder, CO). P1 DNA and plasmid DNA were digested with appropriate restriction enzymes, electrophoresed on agarose gels, and blotted onto Hybond TM -N nitrocellulose filters according to standard procedures (49) . Both prehybridization and hybridization were carried out in 6ϫ SSC, 1ϫ Denhardt's solution, 0.5% SDS, 100 g ml Ϫ1 herring sperm DNA, and 1 ϫ 10 6 cpm ml Ϫ1 of the appropriate 32 P-labeled probes at 65°C. The filters were washed in 1.0ϫ SSC, 0.1% SDS and 2.0ϫ SSC, 0.1% SDS either at 60 -65°C or at room temperature and exposed to x-ray film.
Polymerase Chain Reaction-A 585-bp fragment containing 99 bp of exon Ϫ1A sequence present in the RT-PCR clones and 486 bp of upstream sequence, including CTAAT and TAATA, was amplified from pFM1A1 DNA using primers 3 and 4 (see Table I ) with the eLONGase TM enzyme mix. The reaction consisted of the following cycling temperatures and times: 94°C for 30 s, 60°C for 30 s, and 68°C for 2 min. The resulting amplicon (nt 458 -1042 in Fig. 3B ) was subcloned into pBluescript KS(ϩ) and designated pFM1A6.
To amplify a fragment spanning exons Ϫ1A and Ϫ1B, Ϫ1A-specific primer 2 and Ϫ1B-specific primer 7 (see Table I ) were annealed to P1 7520 and 7521 DNA and then extended with the eLONGase TM enzyme mix according to the following cycling temperatures and times: 94°C for 30 s, 60°C for 30 s, and 68°C for 1 min/kb of product, for 35 cycles. The primers used to amplify DNA between exons Ϫ1G and 1 are primer 8 and primer 1 (see Table I ), and the primers used to amplify DNA between exons Ϫ1C and Ϫ1G are primers 9 and 10 (see Table I ). Both sets of primers were annealed to P1 980 DNA (see Fig. 8A ) and extended with the eLONGase TM enzyme mix, according to the same conditions described above.
Nucleotide Sequencing and DNA Sequence Comparison-All DNA fragments to be sequenced were subcloned into pBluescript KS(ϩ) vector (Stratagene, La Jolla, CA) using T4 DNA ligase (Roche Molecular Biochemicals and Life Technologies). Double stranded sequencing was carried out via the dideoxy chain termination method (50) RNase Protection Analyses-Mouse tissues were harvested and either frozen away at Ϫ80°C or immediately homogenized in 2 ml of RNAzol TM (Tel-Test, Inc., Friendswood, TX)/100 mg of tissue with a glass-Teflon homogenizer. Total RNA was isolated according to the manufacturer's instructions, and its quality was determined on a 1% agarose formamide gel following ethidium bromide staining. RNase protection analysis was carried out as outlined by Ausubel et al. (51) with minor modifications. Briefly, 50 g of total RNA were first mixed with either the antisense riboprobe (5 ϫ 10 5 cpm) alone, or with 2 ϫ 10 4 cpm of mouse glyceraldehyde-3-phosphate dehydrogenase, in a solution of 40 mM PIPES, pH 6.4, 0.4 M NaCl, 1 mM EDTA, pH 8.0, and 80% formamide. The samples were heated at 85-90°C for 5 min, and then immediately transferred to a 42°C water bath and incubated overnight. RNase A (7 g/ml) and T 1 (0.35 g/ml) were used to treat the hybridization reaction products, followed by the addition of SDS-proteinase K (50 g). The protected fragments were recovered by ethanol precipitation and analyzed on a 6% denaturing polyacrylamide gel.
To determine the 3Ј-end of the mouse FGF-1 gene, a 219-bp PstI/ PvuII fragment (nt 3608 -3826 in Fig. 1 ) was subcloned into the PstI/ EcoRV site of pBluescript KS(ϩ) in such an orientation that T3 RNA polymerase could be used for in vitro transcription. The resulting plasmid was designated pFM3E. For the analysis of FGF-1.A versus non-1.A expression, a 445-bp EcoRI/BamHI containing 295 nt of Ϫ1A exon and 150 nt of exon 1 (nt 1-295 and 296 -446, respectively, in Fig. 5C ) was cloned in pBluescript KS(ϩ). The resulting plasmid, designated pFM1A5, was linearized with EcoRI and in vitro transcribed using T7 RNA polymerase. The x-ray films were scanned and analyzed on a LKB 2400 GelScan XL scanner (LKB, Bromma, Sweden). In order to determine the start site of the 1A promoter, pFM1A6 was in vitro transcribed with T7 RNA polymerase.
Reverse Transcription-PCR-Total RNA was prepared from mouse tissues, and its quality was tested as described above. First strand cDNA synthesis was carried out using 1-5 g of RNA by SUPER-SCRIPT II TM RNase H Ϫ reverse transcriptase provided with the SU-PERSCRIPT TM preamplification system (Life Technologies) using primer 1 (see Table I ) as an exon 1-specific antisense primer. The subsequent amplification of the 1.A-exon 1 product was carried out with the eLONGase TM enzyme according to the manufacturer's instructions (Life Technologies) with primers 1 and 2 (see Table I ). Following a 30-s denaturation step at 94°C, the samples were subjected to 35 cycles of amplification at the following temperatures: 94°C for 30 s, 60°C for 30 s, and 68°C for 2 min. The amplified fragment was cloned into EcoRV-digested T-tailed pBluescript KS(ϩ) and designated pFM1A4. Table I ) was annealed to 1 g of total mouse heart RNA and extended according to the manufacturer's instructions of the 5Ј-RACE system, version 2.0 (Life Technologies, Inc.). The dC-tailed cDNA product was subsequently amplified using 400 nM of both abridged anchor primer and primer 6 ( Table I ). The eLONGase TM enzyme mix (Life Technologies) was used in this reaction, which involved the following cycling temperatures and times: 94°C for 30 s, 60°C for 30 s, and 68°C for 60 s for 35 cycles. The resulting amplified products were subcloned into EcoRV-digested T-tailed pBluescript KS(ϩ) and sequenced.
5Ј-Rapid Amplification of cDNA Ends (RACE)-Antisense primer 4 or 5 (see

RESULTS
Characterization of the 3Ј-End of the Mouse FGF-1 Gene-We
have previously isolated overlapping genomic clones that span the mouse FGF-1 coding region (32) , which is composed of three exons. To further characterize the mouse FGF-1 gene and to identify the polyadenylation signal sequences, we sequenced 4005 bp in the 3Ј-end (Fig. 1) . Analysis of 3512 bp of 3Ј untranslated sequence revealed the presence of six putative polyadenylation signals (Fig. 1) located at nt 2408, 2411, 2573 , 2654, 3275, and 3725. The human FGF-1 gene contains two polyadenylation sites located at 3089 and 3101 bp downstream of the termination codon (34) , and the length of the mouse FGF-1 3Ј-UTR was expected to be similar to that of human. Because the size of the major mouse FGF-1 mRNA transcript is 4 kb (52), we expected the AATAAA spanning nt 3725-3730 to be the polyadenylation site of the mouse FGF-1 gene. To demonstrate this point, RNase protection analysis using RNA from kidney, brain, heart, and liver C3H/HeJ mice was carried out (Fig. 2) . BamHI-digested pFM3E DNA, the 219-bp PstI/EcoRV insert of which contains the last putative polyadenylation sequence (AATAAA), was in vitro transcribed with T3 RNA polymerase and used as the riboprobe (Fig. 2) . Only one protected fragment of the expected size (150 nt) was detected, confirming that AATAAA spanning nt 3725-3730 is the polyadenylation signal sequence. This result demonstrated that the mouse Fgf1 3Ј untranslated sequence is 3.2 kb.
Isolation and Characterization of Mouse FGF-1.A Genomic Clones-The FGF-1A exon was isolated by screening of a mouse P1 library using primers designed to amplify a 109-bp fragment from the Ϫ1B exon (43) . Three positive clones (P1 7520, 7521, and 7522) were analyzed by restriction enzyme digestion followed by hybridization to a 0.8-kb EcoRI/HindIII fragment containing the rat Ϫ1A exon (data not shown). A 5.6-kb BglII hybridizing fragment from P1 7521 was subcloned into the BamHI site of pBluescript KS(ϩ) and designated pFM1A. Subsequently, it was characterized by restriction enzyme digestion followed by hybridization to the 0.8-kb EcoRI/ HindIII fragment containing the rat Ϫ1A exon (Fig. 3A) . In order to confirm the presence of the mouse Ϫ1A sequence, a 1375-bp HindIII/EcoRI fragment hybridizing to the rat Ϫ1A probe was subcloned into pBluescript KS(ϩ) and named pFM1A1. Its DNA sequence was determined (Fig. 3B ) and was aligned with that of the human Ϫ1A exon (data not shown), thus enabling us to identify the promoter region. Furthermore, putative CAAT and TATA consensus sequences were also identified at the appropriate position expected, on the basis of their position in the human FGF-1 A exon.
When comparing 629 bp of mouse (nt 747-1375 in Fig. 3B ) with 668 bp of human Ϫ1A sequence (nt 1-668, as determined by Myers et al. (35) ), 66% sequence similarity was observed. In addition, DOTPLOT analysis between mouse and human revealed the presence of six regions with greater than 70% sequence similarity (Fig. 4) , including sequences immediately upstream from the start site.
Characterization of the FGF-1.A Promoter and Expression of its mRNA-In order to obtain an FGF-1.A cDNA, we used RT-PCR. Primer 1, specific to the first protein coding exon, was annealed to RNA derived from mouse kidney, brain, heart, and liver and extended. The resulting cDNAs were amplified using an exon Ϫ1A-specific sense primer (primer 2) as well as primer 1, and visualized on a 1.2% agarose gel (Fig. 5A) , and then hybridized to the pFM1A1 1375-bp EcoRI/HindIII fragment (Fig. 5B) . The 498-bp product amplified from heart RNA was subcloned into EcoRV, T-tailed pBluescript KS(ϩ) and named pFM1A4; sequence analysis confirmed the presence of both the Ϫ1A exon and exon 1, spliced together at the expected site, 34 nucleotides upstream from the ATG (Fig. 5C) .
Based on the study of the human tissues, we know that mononuclear cells, placenta, ovary, prostate, and breast epithelial cells do not express any FGF-1 transcripts (27, 30, 33, 34, 39) and that stomach, duodenum, appendix, and testes are negative for FGF-1 (53). We further showed that macrophages, spleen and lymph nodes did not express FGF-1 mRNA (data not shown). Because human heart and kidney are the most abundant sources of FGF-1.A mRNA, we chose these same mouse tissues, as well as brain, liver, and lung, to assess the expression pattern of the FGF-1.A mRNA species, via RNase protection analysis. The riboprobe used was derived from pFM1A5, which was generated by subcloning a 445-bp EcoRI/ BamHI fragment (which lacks 53 bp of the 3Ј-end of exon 1) from pFM1A4 into pBluescript KS(ϩ) (Fig. 6) . The results, summarized in Table II , confirmed the RT-PCR data by showing the FGF-1.A transcript being more abundant in heart than in any other tissues assayed (Fig. 6) . The 445-nt protected fragment, corresponding to the 1.A mRNA, represents 26.2% of the total FGF-1 mRNA in the heart, whereas in kidney and lung, the 1.A mRNA transcript only comprises 0.4 and 0.3%, respectively, of the total FGF-1 mRNA. Brain and liver displayed only the 150-nt protected fragment, indicating the presence of FGF-1 transcripts other than 1.A in these tissues.
Identification of the Transcription Start Site for FGF-1.A mRNA by RNase Protection Analysis and 5Ј-RACE-
In human, the FGF-1.A transcription start site is located 25 nt downstream of the TATA box (35) . Due to the high sequence similarity between the two species, we expected the mouse Ϫ1A start site to reside at a comparable position. To obtain a suitable template to carry out the RNase protection experiment, primers 3 and 4 were used to amplify a 585-bp product from pFM1A1. The amplicon contains 99 bp of Ϫ1A sequence present in the cDNA clones and 486 bp of upstream sequence containing putative CAAT and TATA boxes. Following subcloning of this fragment into pBluescript KS(ϩ), the resulting DNA, designated pFM1A6, was linearized with HindIII and transcribed in vitro with T7 RNA polymerase (Fig. 7) . The obtained riboprobe was hybridized to 50 g of total mouse kidney and heart RNA. A protected fragment of 176 nt was obtained in the heart lane ( Fig. 7) , thus placing the Ϫ1A start site 374 nt upstream of the splice donor site of exon Ϫ1A.
To confirm this finding, 5Ј-RACE was carried out. Heart RNA was used as a template to extend Ϫ1A cDNA using antisense primer 4 and/or 5. Following PCR amplification using primer 6 as an antisense nested primer and an abridged anchor primer as a sense primer, the samples were run on a 1.2% agarose gel and transferred to a nylon filter. Hybridization to the pFM1A6 EcoRI/HindIII insert containing the 5Ј-end of the 1A promoter revealed a band of approximately 150 bp (data not shown). This band was observed only in the heart lanes, consistent with our RT-PCR and RNase protection re- . Three g of RNA were reverse-transcribed using primer 1 (see Table I ). The cDNA was then amplified by PCR with primers 1 and 2 from Table I (underlined in C). The resulting products were first electrophoresed on a 1.2% agarose gel (A) and then hybridized to the 1375-bp EcoRI/HindIII genomic fragment containing the mouse Ϫ1A exon (B). The marker is bacteriophage DNA digested with HindIII and X174 DNA digested with HaeIII. The 498-bp PCR product in A, lane 3, was cloned into pBluescript KS(ϩ) and designated pFM1A4. Its sequence is shown in C. The arrow (C) indicates the splicing of Ϫ1A to exon 1. The initiation codon is underlined. sults. Upon nucleotide sequence analysis of five independent clones, obtained from the cloning of this ϳ150-bp fragment into T-tailed pBluescript KS(ϩ), we established that two of the clones had their 5Ј-end at nt 872 and three at nt 873 (Fig. 3B) , which is seven and eight nucleotides downstream of the start site, respectively, as determined by RNase protection analysis.
Characterization of the Mouse FGF-1 Gene-The position of exon Ϫ1A relative to Ϫ1B was determined via long range PCR using a set of primers specific to each exon (primers 2 and 7, respectively). A PCR product of approximately 10 kb was detected. Following digestion with EcoRI and BglII, both alone and together, this fragment was hybridized to the following 32 P-labeled fragments: a 1375-bp EcoRI/HindIII fragment containing the Ϫ1A exon, a 2.5-kb EcoRI fragment of the mouse FGF-1 cDNA containing 112 bp of Ϫ1B exon, and the PCR product itself. Based on the hybridization results (data not shown) and on the basis of the available restriction map around these two exons, we determined the size of the distance between Ϫ1A and Ϫ1B to be 10.7 kb (Fig. 8B) . To determine the distance between exons Ϫ1C and Ϫ1G and between exons Ϫ1G and 1, we used long range PCR as described under "Experimental Procedures." The sizes of the amplicons are 16 and 8.2 kb, respectively (data not shown). Therefore, the position of these two upstream untranslated exons are 23.6 and 7.8 kb upstream of exon 1, respectively (Fig. 8A) . Based on the size of the P1 980 DNA (78.5 kb), the position of Ϫ1B relative to the 5Ј-end of P1 980, and the overlapping region between clones 980 and 981, we determined the size of the intron separating Ϫ1B and the first protein-coding exon to be 59 kb (Fig. 8A) . Therefore, the mouse FGF-1 gene spans over 90 kb.
DISCUSSION
Mapping of the end of the mouse FGF-1 gene revealed the presence of a long 3Ј-untranslated region, consistent with the human FGF-1 gene structure. We have identified the major polyadenylation site, residing 3231 bp downstream from the stop codon, by RNase protection analysis (Fig. 2) . Furthermore, no additional AATAAA sequences were detected 275 bp beyond this polyadenylation site. In comparison, the two major polyadenylation signals in human reside 3090 and 3102 bp 3Ј of the stop codon (34) . Minor differences between the two species are to be expected, although the crucial features of this gene are conserved. Indeed, the 3Ј-UTR of the mouse and human FGF-1 genes share 60.4% sequence similarity, with stretches sharing more than 80% similarity. The region immediately upstream from the major polyadenylation signal (nt 3696 -3734 in Fig. 1 ) shares 87% sequence similarity with the corresponding human sequence. In contrast, the sequence similarity of the region downstream from the polyadenylation signal (nt 3735-3794) dropped to 45%.
The conservation observed in the Fgf1 3Ј-UTR among different species, along with the presence of long 3Ј-UTRs in genes involved in modulation of cellular proliferation (54, 55) 2 kb) , respectively, were characterized by restriction mapping and DNA sequence analysis. PCR 1 designates the 11.1-kb PCR fragment spanning exons Ϫ1A and Ϫ1B (detailed in B); PCR 2 designates the 11.7-kb PCR product spanning the first and second protein coding exons; fran1 is a phage clone containing a 12.9-kb insert that spans exons 2 and 3. The positions of exons Ϫ1C and Ϫ1G were determined by long range PCR amplification of DNA encompassing exons Ϫ1C and Ϫ1G and exons Ϫ1G and 1, respectively. The dashed lines represent the splicing of Ϫ1A and Ϫ1B to the first protein coding exon. The DNA in fran1 not derived from the Fgf1 locus is indicated with a dotted line. The double dashed line denotes that the boundary of P1 7521 DNA has not been determined. B, primers 2 and 7 (see Table I ) were used to amplify an 11.1-kb fragment from P1 7521 DNA. E, EcoRI; G, BglII; N, NotI. The boxes represent the amplified regions of exons Ϫ1A (left) and Ϫ1B (right), which are 295 and 151 bp, respectively. pFM1A was subcloned from P1 7521 DNA, whereas pKA7 and pKA8 were subcloned from P1 980 DNA. The insert sizes are shown below each clone. The double dashed line represents vector DNA derived from P1 clone 980. The NotI site shown in pKA8 is in the multiple cloning site of the P1 vector. a functional significance of this area. Indeed, the expression of the hst/K-FGF proto-oncogene is controlled by regulatory elements present in the 3Ј-end (56) . Both human (34) and mouse Fgf1 3Ј-UTRs contain AU-rich elements (57) , which may be partly responsible for the transient expression of certain messages, particularly FGF-1.C (30, 38) . In fact, the levels of this particular mRNA are dramatically increased upon phorbol 12-myristate 13-acetate, serum, and transforming growth factor-␤ stimulation. These observations point to a more complex mechanism of Fgf1 regulation, as it cannot be ruled out that the 5Ј and 3Ј untranslated regions work in concert to dictate the fate of a particular FGF-1 message in response to external stimuli in a given cellular milieu.
Screening of a mouse P1 library using primers specific to the mouse Ϫ1B exon allowed for the isolation of exon Ϫ1A. In addition, having obtained a clone spanning both exons allowed us to determine the size of the intron separating them, which is very similar to that of human (10.7 versus 11.7 kb) (Fig. 8B) . In contrast, when DNA sequence comparison was carried out in order to find the Ϫ1A chicken homologue among 5 upstream untranslated exons recently isolated (58) , no significant sequence similarity was observed with any of the 5Ј-UTRs tested. These differences between the mouse and chicken upstream untranslated exons are possibly due to the greater evolutionary distance that exists between avian and mammalian species. Nonetheless, the presence of 5Ј-UTRs, as diverse as they may be, in species that are evolutionary divergent, further confirms the complexity of this growth factor gene, and the need for a stringent regulation of its expression.
Finally, further characterization of the mouse Ϫ1A revealed that, like that of human, this promoter also contains TATA and CAAT sequence variants, located at comparable distance from the transcriptional start site of the exon. Indeed, as established by RNase protection analysis (Fig. 7) , the mouse Ϫ1A exon is 374 bp in size, which differs from its human homologue by only 24 bp.
While attempting to obtain an RT-PCR product containing the Ϫ1A exon spliced to exon 1, we determined that the mouse heart is the most abundant source of FGF-1.A mRNA (Fig. 5) . These data were further confirmed by RNase protection (Fig.  6) , although this analysis also demonstrated that other FGF-1 mRNA species are present in this particular tissue. Upon searching for putative transcription factor binding sites in the FGF-1.A promoter region (59), we discovered the presence of several AP-1 binding sites (Fig. 3B) , and a single putative binding site for c-Myb. It is noteworthy that both c-Myb and FGF-1 are involved in vascular smooth muscle cell proliferation, and tissue repair of the neointima following angioplasty (60) . Although there is no evidence that these two genes are involved in the same signaling pathway, it is not to be excluded that c-Myb is activated first, and in turn this nuclear protein activates FGF-1 transcription. Antisense nucleotides against c-Myb inhibit cell proliferation and neointima formation (61) , as well as reducing the steady state levels of the corresponding mRNA and protein in a dose-dependent manner in vitro. Thus, it is likely that c-Myb expression in response to vascular injury serves as an activator for FGF-1 and other growth factors that promote angiogenesis and tissue repair. Ultimately, however, DNase I footprinting and electromobility shift assay would demonstrate this interaction, the functionality of which would in turn be proven by the appropriate promoter studies.
Characterization of the entire transcription unit of the mouse FGF-1 gene (Fig. 8A ) has enabled us to compare it with its human homologue. This information will be valuable for the development of knockout constructs used in homologous recombination for generating transgenic mice in an effort to determine the functional significance of the 1A promoter in heart. Furthermore, it will be important to examine the expression of FGF-1.A in the developing mouse, in order to assess any changes during the life span of the animal, from the embryonic stage to adulthood. Second, because FGF-1 expression has been correlated with cell survival in vascular endothelial cells, such function could be attributable specifically to the FGF-1.A mRNA. Finally, having determined the position of the mouse Ϫ1G exon in the Fgf1 locus will be useful in isolating the human homologue of this recently identified exon.
